Hot Products

Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.

Hot products from the professional high-purity natural products manufacturer

Cat.No. Product Name
BCN1059 Huperzine B
Huperzine B is a efficient inhibitor of human brain AChE, it can enhance ognitive and protect neuro, may be potentially new drug candidates for Alzheimer's disease therapy.
BCN1060 Lovastatin
Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM in a cell-free assay, has a direct cellular effect independent of a cholesterol-lowering effect and delays the onset and progression of diabetic nephropathy. It has a potential application to treat PD via antioxidant effect, and it promotes fibrosis and epithelial to mesenchymal transition, by regulating the production of CCN2 in human gingival fibroblasts.
BCN1061 Formononetin
Formononetin is a phytoestrogen, could be used in postmenopausal osteoporosis. It has antitumorigenic effects, suppressed the proliferation of human non-small cell lung cancer through induction of cell cycle arrest and apoptosis; it also exhibits antiviral activities against some members of Picornaviridae, could inhibit EV71-induced COX-2 expression and PGE2 production via MAPKs pathway including ERK, p38 and JNK.
BCN1062 Pseudoginsenoside F11
Pseudoginsenoside F11, a novel partial PPAR γ agonist, can promote adiponectin oligomerization and secretion in 3T3-L1 adipocytes and inhibit obesity-linked phosphorylation of PPAR γ at Ser-273 by Cdk5. It possesses significant neuroprotective activity, has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice; it also antagonizes the development of analgesia tolerance to morphine and blocks the development of morphine-induced behavioral sensitization via its effect, at least partially, on the glutamatergic system in the mPFC.
BCN1063 Ginsenoside Rb1
Ginsenoside Rb1 is a protopanaxadiol that has diverse in vitro and in vivo effects, including neuroprotective, cardioprotective, anti-obesity, anti-inflammatory, and anti-oxidative actions. Ginsenoside Rb1 can up-regulate the expression of GLUTs in adipose tissue, in addition to activate insulin signalling pathway, and may effectively ameliorate the progression of asthma through Relegating Th1/Th2. It inhibited Na+, K+-ATPase activity with an IC50 of 6.3±1.0 μM, activated Akt, phosphorylating GSK-3β and inhibited mPTP opening.
BCN1064 Ginsenoside Rb2
Ginsenoside Rb2 shows hypoglycemic, anti-osteoporosis, anti-oxidant, anti-angiogenesis, and anti-tumor activities, it is a promising candidate as a mucosal immunoadjuvant to enhance antiviral activity and is a valuable component capable of lowering the levels of lipids. Ginsenoside Rb2 also possesses a protective role against the photoaging of human keratinocyte cells under UV-B irradiation, shows inhibitory effects on nicotinic stimulation-evoked catecholamine secretion, at least partly through the increased NO production due to the activation of nitric oxide synthase, which is relevant to neuronal nicotinic receptor blockade.
BCN1065 Ginsenoside Rb3
Ginsenoside Rb3 has anti-myocardial ischemia-reperfusion injury, neuroprotective, antidepressant-like, and antioxidant effects, it also possesses the potential of the clinical use in preventing and treating diabetes. Ginsenoside Rb3 significantly attenuates the changes of creatine kinase activity and lactate dehydrogenase activity, exhibits inhibitory effect on TNFα-induced NF-κB transcriptional activity with an IC50 of 8.2 μM in 293T cell lines, it also inhibits the induction of COX-2 and iNOS mRNA.
BCN1066 Ginsenoside Rg1
Ginsenoside Rg1 has antiaging, anti-platelet activation, promotion of wound healing, and neuroprotective effects, it has protective effect against Aβ25-35-induced toxicity in PC12 cells,might be through the insulin-like growth factor-I receptor (IGF-IR) and estrogen receptor (ER)signaling pathways. Ginsenoside Rg1 is a desirable agent for enhancing CD4+ T-cell activity, as well as the correction of Th1-dominant pathological disorders, which by increasing Th2 specific cytokine secretion and by repressing Th1 specific cytokine production. It increased the expression of the vascular endothelial growth factor (VEGF) mRNA and reduced ERK pathway, expression of transforming growth factor beta (TGF-β) mRNA.